Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incidence of skin neoplasia after ingenol disoxate treatment in actinic keratosis
2017-000228-85Phase 3Terminated
- Sponsor
- LEO Pharma
- Start
- Apr 2017
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ingenol disoxate in actinic keratosis (AK) (3 arms), sponsored by LEO Pharma. Primary endpoint: Time to first squamous cell carcinoma in the treatment area. Started Apr 2017; status: terminated.
02
Drugs
ingenol disoxate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2017-000228-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000228-85.